Polyinosinic polycytidylic acid (pIC) has potential as a vaccine against pancreatic cancer. When administered to healthy mice, it slowed the growth of subsequent tumors by 60%. The study was published on: Journal of Cancer Immunotherapy.
Pancreatic cancer is one of the most difficult tumors to treat. The annual survival rate is 24%, and only 9% will live more than five years after cancer is detected. In a new study, scientists demonstrated that delivery of pIC directly to a tumor cell using a water-soluble polyethyleneimine polymer allowed the destruction of pancreatic ductal adenocarcinoma cells.
Additionally, tests in mice showed that pIC slowed tumor growth by approximately 60% when administered before cancer development, meaning it had a vaccine-like effect. The molecule significantly extended the animals’ lives by rewiring their immune systems to attack the tumor and was also safe and non-toxic to normal pancreatic cells. The authors of the study noted that similar results had not been obtained before. The substance is currently ready for testing on humans.
Previous scientists I learnedCT scans increase the risk of blood cancer.